Enoblituzumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from mouse) |
| Target | B7-H3 |
| Identifiers | |
| CAS Number | 1353485-38-7 |
| ATC code | none |
| Chemical data | |
| Formula | C6474H9990N1726O2030S42 |
| Molecular mass | 145.8 kg/mol |
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.
This drug was developed by MacroGenics, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibody stubs
- Monoclonal antibodies
